Do analysts rate POAI or NRXS?

NeurAxis has a consensus price target of $13.00, suggesting a potential upside of 91.18%. Given NeurAxis' stronger consensus rating and higher probable upside, analysts plainly believe NeurAxis is more favorable than Predictive Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Predictive Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NeurAxis 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Do analysts prefer OM or POAI?

Outset Medical presently has a consensus target price of $10.00, indicating a potential upside of 147.52%. Given Outset Medical's stronger consensus rating and higher possible upside, equities analysts clearly believe Outset Medical is more favorable than Predictive Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Outset Medical 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Predictive Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer POAI or SPAI?

Safe Pro Group has a consensus price target of $11.00, suggesting a potential upside of 202.20%. Given Safe Pro Group's stronger consensus rating and higher possible upside, analysts plainly believe Safe Pro Group is more favorable than Predictive Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Predictive Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Safe Pro Group 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Do analysts recommend POAI or NNOX?

Nano-X Imaging has a consensus target price of $4.00, suggesting a potential upside of 346.33%. Given Nano-X Imaging's stronger consensus rating and higher possible upside, analysts plainly believe Nano-X Imaging is more favorable than Predictive Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Predictive Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Nano-X Imaging 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 2.67

Do analysts prefer LNSR or POAI?

LENSAR currently has a consensus target price of $10.00, suggesting a potential upside of 78.57%. Given LENSAR's stronger consensus rating and higher probable upside, equities research analysts clearly believe LENSAR is more favorable than Predictive Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LENSAR 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Predictive Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is LNSR or POAI more profitable?

LENSAR has a net margin of 50.94% compared to Predictive Oncology's net margin of -5,065.23%. LENSAR's return on equity of -183.19% beat Predictive Oncology's return on equity. Company Net Margins Return on Equity Return on Assets LENSAR 50.94% -183.19% 42.26% Predictive Oncology -5,065.23% -732.73% -235.55%

Predictive Oncology (POAI) Competitors

$6.85 -0.51 (-6.93%)

As of 07/24/2026

Compare

POAI vs. NRXS, OM, SPAI, NNOX, and LNSR

Should you buy Predictive Oncology stock or one of its competitors? MarketBeat compares Predictive Oncology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Predictive Oncology include NeurAxis (NRXS), Outset Medical (OM), Safe Pro Group (SPAI), Nano-X Imaging (NNOX), and LENSAR (LNSR). These companies are all part of the "medical equipment" industry.

How does Predictive Oncology compare to NeurAxis?

Predictive Oncology (NASDAQ:POAI) and NeurAxis (NASDAQ:NRXS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations.

NeurAxis has a consensus price target of $13.00, suggesting a potential upside of 91.18%. Given NeurAxis' stronger consensus rating and higher probable upside, analysts plainly believe NeurAxis is more favorable than Predictive Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Predictive Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NeurAxis	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Predictive Oncology has a beta of 1.35, suggesting that its share price is 35% more volatile than the broader market. Comparatively, NeurAxis has a beta of 1.43, suggesting that its share price is 43% more volatile than the broader market.

Predictive Oncology has higher earnings, but lower revenue than NeurAxis. NeurAxis is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Predictive Oncology	$1.66M	13.97	-$12.66M	-$13.50	N/A
NeurAxis	$4.28M	19.67	-$14.63M	-$0.81	N/A

NeurAxis has a net margin of -492.76% compared to Predictive Oncology's net margin of -5,065.23%. NeurAxis' return on equity of 0.00% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Predictive Oncology	-5,065.23%	-732.73%	-235.55%
NeurAxis	-492.76%	N/A	-641.25%

9.0% of Predictive Oncology shares are held by institutional investors. Comparatively, 11.8% of NeurAxis shares are held by institutional investors. 1.2% of Predictive Oncology shares are held by company insiders. Comparatively, 21.1% of NeurAxis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, NeurAxis had 1 more articles in the media than Predictive Oncology. MarketBeat recorded 1 mentions for NeurAxis and 0 mentions for Predictive Oncology. NeurAxis' average media sentiment score of 0.75 beat Predictive Oncology's score of 0.00 indicating that NeurAxis is being referred to more favorably in the news media.

Company	Overall Sentiment
Predictive Oncology	Neutral
NeurAxis	Positive

Summary

NeurAxis beats Predictive Oncology on 13 of the 16 factors compared between the two stocks.

How does Predictive Oncology compare to Outset Medical?

Outset Medical (NASDAQ:OM) and Predictive Oncology (NASDAQ:POAI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations, media sentiment and institutional ownership.

Predictive Oncology has lower revenue, but higher earnings than Outset Medical. Outset Medical is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Outset Medical	$117.59M	0.64	-$81.65M	-$4.16	N/A
Predictive Oncology	$1.66M	13.97	-$12.66M	-$13.50	N/A

Outset Medical has a beta of 1.95, indicating that its stock price is 95% more volatile than the broader market. Comparatively, Predictive Oncology has a beta of 1.35, indicating that its stock price is 35% more volatile than the broader market.

Outset Medical presently has a consensus target price of $10.00, indicating a potential upside of 147.52%. Given Outset Medical's stronger consensus rating and higher possible upside, equities analysts clearly believe Outset Medical is more favorable than Predictive Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Outset Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Predictive Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Outset Medical has a net margin of -63.65% compared to Predictive Oncology's net margin of -5,065.23%. Outset Medical's return on equity of -56.13% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Outset Medical	-63.65%	-56.13%	-27.45%
Predictive Oncology	-5,065.23%	-732.73%	-235.55%

9.0% of Predictive Oncology shares are held by institutional investors. 2.5% of Outset Medical shares are held by insiders. Comparatively, 1.2% of Predictive Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Outset Medical had 4 more articles in the media than Predictive Oncology. MarketBeat recorded 4 mentions for Outset Medical and 0 mentions for Predictive Oncology. Outset Medical's average media sentiment score of 1.23 beat Predictive Oncology's score of 0.00 indicating that Outset Medical is being referred to more favorably in the media.

Company	Overall Sentiment
Outset Medical	Positive
Predictive Oncology	Neutral

Summary

Outset Medical beats Predictive Oncology on 12 of the 16 factors compared between the two stocks.

How does Predictive Oncology compare to Safe Pro Group?

Predictive Oncology (NASDAQ:POAI) and Safe Pro Group (NASDAQ:SPAI) are both small-cap medical equipment companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

Predictive Oncology has a beta of 1.35, suggesting that its share price is 35% more volatile than the broader market. Comparatively, Safe Pro Group has a beta of 3.52, suggesting that its share price is 252% more volatile than the broader market.

In the previous week, Safe Pro Group had 1 more articles in the media than Predictive Oncology. MarketBeat recorded 1 mentions for Safe Pro Group and 0 mentions for Predictive Oncology. Safe Pro Group's average media sentiment score of 0.95 beat Predictive Oncology's score of 0.00 indicating that Safe Pro Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Predictive Oncology	Neutral
Safe Pro Group	Positive

9.0% of Predictive Oncology shares are owned by institutional investors. 1.2% of Predictive Oncology shares are owned by company insiders. Comparatively, 54.8% of Safe Pro Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Safe Pro Group has a net margin of -800.91% compared to Predictive Oncology's net margin of -5,065.23%. Safe Pro Group's return on equity of -119.17% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Predictive Oncology	-5,065.23%	-732.73%	-235.55%
Safe Pro Group	-800.91%	-119.17%	-107.17%

Predictive Oncology has higher revenue and earnings than Safe Pro Group. Safe Pro Group is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Predictive Oncology	$1.66M	13.97	-$12.66M	-$13.50	N/A
Safe Pro Group	$610K	124.66	-$14.32M	-$0.71	N/A

Safe Pro Group has a consensus price target of $11.00, suggesting a potential upside of 202.20%. Given Safe Pro Group's stronger consensus rating and higher possible upside, analysts plainly believe Safe Pro Group is more favorable than Predictive Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Predictive Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Safe Pro Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Safe Pro Group beats Predictive Oncology on 13 of the 17 factors compared between the two stocks.

How does Predictive Oncology compare to Nano-X Imaging?

Predictive Oncology (NASDAQ:POAI) and Nano-X Imaging (NASDAQ:NNOX) are both small-cap medical equipment companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.

9.0% of Predictive Oncology shares are held by institutional investors. Comparatively, 21.5% of Nano-X Imaging shares are held by institutional investors. 1.2% of Predictive Oncology shares are held by company insiders. Comparatively, 7.7% of Nano-X Imaging shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Nano-X Imaging has a net margin of -716.44% compared to Predictive Oncology's net margin of -5,065.23%. Nano-X Imaging's return on equity of -70.96% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Predictive Oncology	-5,065.23%	-732.73%	-235.55%
Nano-X Imaging	-716.44%	-70.96%	-62.26%

Predictive Oncology has a beta of 1.35, meaning that its share price is 35% more volatile than the broader market. Comparatively, Nano-X Imaging has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market.

Nano-X Imaging has a consensus target price of $4.00, suggesting a potential upside of 346.33%. Given Nano-X Imaging's stronger consensus rating and higher possible upside, analysts plainly believe Nano-X Imaging is more favorable than Predictive Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Predictive Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Nano-X Imaging	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.67

Predictive Oncology has higher earnings, but lower revenue than Nano-X Imaging. Nano-X Imaging is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Predictive Oncology	$1.66M	13.97	-$12.66M	-$13.50	N/A
Nano-X Imaging	$14.52M	4.30	-$75.02M	-$1.58	N/A

In the previous week, Nano-X Imaging had 21 more articles in the media than Predictive Oncology. MarketBeat recorded 21 mentions for Nano-X Imaging and 0 mentions for Predictive Oncology. Nano-X Imaging's average media sentiment score of 0.07 beat Predictive Oncology's score of 0.00 indicating that Nano-X Imaging is being referred to more favorably in the news media.

Company	Overall Sentiment
Predictive Oncology	Neutral
Nano-X Imaging	Neutral

Summary

Nano-X Imaging beats Predictive Oncology on 13 of the 17 factors compared between the two stocks.

How does Predictive Oncology compare to LENSAR?

LENSAR (NASDAQ:LNSR) and Predictive Oncology (NASDAQ:POAI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership and risk.

40.2% of LENSAR shares are owned by institutional investors. Comparatively, 9.0% of Predictive Oncology shares are owned by institutional investors. 65.8% of LENSAR shares are owned by insiders. Comparatively, 1.2% of Predictive Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

LENSAR has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market. Comparatively, Predictive Oncology has a beta of 1.35, suggesting that its stock price is 35% more volatile than the broader market.

In the previous week, LENSAR had 2 more articles in the media than Predictive Oncology. MarketBeat recorded 2 mentions for LENSAR and 0 mentions for Predictive Oncology. LENSAR's average media sentiment score of 0.93 beat Predictive Oncology's score of 0.00 indicating that LENSAR is being referred to more favorably in the media.

Company	Overall Sentiment
LENSAR	Positive
Predictive Oncology	Neutral

Predictive Oncology has lower revenue, but higher earnings than LENSAR. LENSAR is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENSAR	$57.70M	1.19	-$34.28M	-$0.58	N/A
Predictive Oncology	$1.66M	13.97	-$12.66M	-$13.50	N/A

LENSAR has a net margin of 50.94% compared to Predictive Oncology's net margin of -5,065.23%. LENSAR's return on equity of -183.19% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LENSAR	50.94%	-183.19%	42.26%
Predictive Oncology	-5,065.23%	-732.73%	-235.55%

LENSAR currently has a consensus target price of $10.00, suggesting a potential upside of 78.57%. Given LENSAR's stronger consensus rating and higher probable upside, equities research analysts clearly believe LENSAR is more favorable than Predictive Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENSAR	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Predictive Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

LENSAR beats Predictive Oncology on 12 of the 16 factors compared between the two stocks.

Get Predictive Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding POAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

POAI vs. The Competition

Export

Metric	Predictive Oncology	MEDICAL INFO SYS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$23.25M	$1.68B	$6.86B	$12.25B
Dividend Yield	N/A	N/A	2.67%	9.79%
P/E Ratio	-0.51	74.42	27.14	23.64
Price / Sales	13.97	62.75	517.01	89.03
Price / Cash	N/A	26.11	50.54	59.64
Price / Book	-14.89	4.98	10.28	6.07
Net Income	-$12.66M	-$54.76M	$3.60B	$331.99M
7 Day Performance	-0.29%	-6.95%	-1.27%	-0.63%
1 Month Performance	5.87%	-2.60%	-0.37%	-2.00%
1 Year Performance	-42.87%	-11.12%	18.30%	13.62%

Predictive Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
POAI Predictive Oncology	N/A	$6.85 -6.9%	N/A	-38.7%	$23.25M	$1.66M	N/A	30
NRXS NeurAxis	1.7968 of 5 stars	$7.15 +3.9%	$13.00 +81.8%	+146.4%	$88.55M	$4.28M	N/A	19
OM Outset Medical	3.5352 of 5 stars	$4.54 +4.1%	$10.00 +120.3%	-77.1%	$80.82M	$119.48M	N/A	520	News Coverage Positive News Gap Down
SPAI Safe Pro Group	3.198 of 5 stars	$3.84 +4.1%	$10.00 +160.4%	-3.2%	$77.06M	$610K	N/A	11
NNOX Nano-X Imaging	2.643 of 5 stars	$1.06 +1.0%	$4.00 +277.4%	-82.8%	$73.07M	$13.02M	N/A	190	Trending News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:POAI) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Predictive Oncology (POAI) Competitors

POAI vs. NRXS, OM, SPAI, NNOX, and LNSR

How does Predictive Oncology compare to NeurAxis?

Summary

How does Predictive Oncology compare to Outset Medical?

Summary

How does Predictive Oncology compare to Safe Pro Group?

Summary

How does Predictive Oncology compare to Nano-X Imaging?

Summary

How does Predictive Oncology compare to LENSAR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

POAI vs. The Competition

Predictive Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Predictive Oncology (POAI) Competitors

POAI vs. NRXS, OM, SPAI, NNOX, and LNSR

How does Predictive Oncology compare to NeurAxis?

Do analysts rate POAI or NRXS?

Which has more risk & volatility, POAI or NRXS?

Which has preferable valuation & earnings, POAI or NRXS?

Is POAI or NRXS more profitable?

Do insiders and institutionals have more ownership in POAI or NRXS?

Does the media favor POAI or NRXS?

Summary

How does Predictive Oncology compare to Outset Medical?

Which has higher earnings & valuation, OM or POAI?

Which has more volatility & risk, OM or POAI?

Do analysts prefer OM or POAI?

Is OM or POAI more profitable?

Do institutionals and insiders believe in OM or POAI?

Does the media refer more to OM or POAI?

Summary

How does Predictive Oncology compare to Safe Pro Group?

Which has more risk & volatility, POAI or SPAI?

Does the media prefer POAI or SPAI?

Do institutionals and insiders hold more shares of POAI or SPAI?

Is POAI or SPAI more profitable?

Which has better valuation & earnings, POAI or SPAI?

Do analysts prefer POAI or SPAI?

Summary

How does Predictive Oncology compare to Nano-X Imaging?

Do institutionals and insiders hold more shares of POAI or NNOX?

Is POAI or NNOX more profitable?

Which has more volatility and risk, POAI or NNOX?

Do analysts recommend POAI or NNOX?

Which has better earnings and valuation, POAI or NNOX?

Does the media prefer POAI or NNOX?

Summary

How does Predictive Oncology compare to LENSAR?

Do insiders & institutionals hold more shares of LNSR or POAI?

Which has more volatility and risk, LNSR or POAI?

Does the media favor LNSR or POAI?

Which has better valuation and earnings, LNSR or POAI?

Is LNSR or POAI more profitable?

Do analysts prefer LNSR or POAI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

POAI vs. The Competition

Predictive Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools